No Data
No Data
Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Incyte's BET Inhibitor Program Holds Promise Amid Safety Concerns and Strategic Uncertainty
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304 Trial Met Primary Endpoint Of Overall Survival...
No Data